Unexpected findings of study of selegiline have not been treated with caution its authors advised

BMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7104.370a (Published 09 August 1997) Cite this as: BMJ 1997;315:370
  1. Mark T Silva, Specialist registrara,
  2. Anthony H V Schapira, Professora,
  3. Peter Jenner, Directorb
  1. a Department of Neurology, Royal Free Hospital, London NW3 2QG
  2. b Neurodegenerative Diseases Research Centre, Pharmacology Group, King's College London, London SW3 6LX

    Editor—In 1995 the BMJ published the results of a study by the Parkinson's Disease Research Group of the United Kingdom comparing the use of levodopa and a peripheral decarboxylase inhibitor either with or without selegiline.1 An unexpected finding was an increase in mortality in the group receiving selegiline. The authors stated at that time that “the difference in mortality should be treated with caution.” An editorial in the same issue also suggested that the findings provided “strong evidence against selegiline having a neuroprotective …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription